Pharmaceutical Processing

North America is expected to continue to lead global pharmaceutical sales in the year 2022, with $635 billion expected that year, according to a March 2019 report from biopharmaceutical company AstraZeneca. The United States, China, Japan, Germany and France led the world pharmaceutical sales market in 2018, with the United States having 47.2 percent of…

The U.S. Food and Drug Administration today approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality. “Today’s approval marks another milestone in the transformational power of gene…

The increasing strategic alliances are expected to trigger the progressive supranuclear palsy therapeutics market growth during the forecast period. Vendors in the market are entering into strategic alliances for co-developing and co-commercializing drugs of for licensing the drugs to large pharmaceutical vendors including the academic institutions and several small pharmaceutical vendors lacking the advanced manufacturing…

Pharma 4.0, an operating model for pharmaceutical factories and supply chains is based on Industry 4.0 capabilities, digital maturity, and data integrity by design. It focuses on technology, integration, work force and quality control. It is fueled by developments in big data, interconnectivity, collaborative robotics, artificial intelligence and distributed cloud service-based architectures. Digitalization is enabling…

Dr. Graham Brearley always has had a passion for applied biology, and when he was exposed to protein biochemistry during his college years, he claims the rest was simply “a natural progression.” Brearley explained that his childhood fascination with biology attracted him to the field of biologics, specifically. “I particularly enjoyed the application of biology, as opposed to just the academic study of…

Consider this scenario: a potentially curative multiple sclerosis therapy is awaiting FDA approval. The pharmaceutical manufacturer has a lot at stake with this product—the company has spent decades discovering, researching and developing this medicine and put tremendous investment behind it. A million people in the U.S. are waiting anxiously for this drug to transform their lives and rid them of their disease.1 While…

It is often said that the one constant is change. And in the world of pharmaceutical research and development in the last decade or so, this is particularly evident.  Not only has the criteria behind intellectual property (IP) protection and patentability changed, but so has the size and shape of research organizations, as well as drug targets. Until recently, companies were primarily…

The past decade has seen a significant positive evolution in the field of immuno-oncology (IO). The introduction of checkpoint inhibition therapies and adoptive cell transfer therapy (ACT) resulted in some excellent improvements in five-year survival rates in patients with hematologic cancers, as well as in certain patients with solid tumors. The first checkpoint-inhibiting antibody therapies have been approved by the U.S.…